Nomura Holdings Inc. acquired a new stake in Impax Laboratories Inc. (NASDAQ:IPXL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 141,697 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,172,000. Nomura Holdings Inc. owned approximately 0.20% of Impax Laboratories as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Seven Bridges Advisors LLC increased its position in Impax Laboratories by 0.3% in the second quarter. Seven Bridges Advisors LLC now owns 32,190 shares of the specialty pharmaceutical company’s stock valued at $928,000 after buying an additional 108 shares during the last quarter. Boston Advisors LLC boosted its stake in shares of Impax Laboratories by 1.1% in the second quarter. Boston Advisors LLC now owns 11,785 shares of the specialty pharmaceutical company’s stock valued at $340,000 after buying an additional 125 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Impax Laboratories by 1.0% in the second quarter. Mackenzie Financial Corp now owns 20,587 shares of the specialty pharmaceutical company’s stock valued at $593,000 after buying an additional 200 shares during the period. Public Employees Retirement System of Ohio boosted its stake in shares of Impax Laboratories by 0.7% in the second quarter. Public Employees Retirement System of Ohio now owns 45,803 shares of the specialty pharmaceutical company’s stock valued at $1,320,000 after buying an additional 323 shares during the period. Finally, Teacher Retirement System of Texas boosted its stake in shares of Impax Laboratories by 5.2% in the second quarter. Teacher Retirement System of Texas now owns 8,615 shares of the specialty pharmaceutical company’s stock valued at $248,000 after buying an additional 424 shares during the period. Institutional investors own 88.17% of the company’s stock.

Shares of Impax Laboratories Inc. (NASDAQ:IPXL) opened at 26.15 on Monday. The stock has a 50 day moving average price of $25.83 and a 200-day moving average price of $30.72. The firm has a market cap of $1.86 billion, a PE ratio of 55.40 and a beta of 1.20. Impax Laboratories Inc. has a 52-week low of $20.97 and a 52-week high of $45.00.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by $0.11. Impax Laboratories had a net margin of 3.78% and a return on equity of 11.30%. The business earned $173 million during the quarter, compared to analyst estimates of $223.67 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s revenue was down 19.4% on a year-over-year basis. On average, equities analysts anticipate that Impax Laboratories Inc. will post $1.59 EPS for the current fiscal year.

Several analysts have issued reports on the company. JPMorgan Chase & Co. assumed coverage on Impax Laboratories in a research report on Wednesday, June 1st. They set a “neutral” rating and a $47.00 target price on the stock. Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $34.00 target price on the stock in a research report on Tuesday, July 12th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $41.00 target price on shares of Impax Laboratories in a research report on Friday, May 27th. Goldman Sachs Group Inc. assumed coverage on Impax Laboratories in a research report on Monday, June 6th. They set a “sell” rating and a $33.00 target price on the stock. Finally, WallachBeth Capital dropped their target price on Impax Laboratories from $40.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $33.93.

In related news, Director Leslie Z. Benet sold 10,092 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $22.81, for a total value of $230,198.52. Following the transaction, the director now directly owns 40,225 shares in the company, valued at $917,532.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.30% of the stock is owned by corporate insiders.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

5 Day Chart for NASDAQ:IPXL

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories Inc. (NASDAQ:IPXL).

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.